{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:19:10Z","timestamp":1780701550610,"version":"3.54.1"},"reference-count":216,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Flavivirus infections, including dengue, Zika, West Nile, and Japanese encephalitis, remain a major global health concern. Although several vaccines are licensed, the durability and qualitative features of vaccine-induced antibodies differ substantially across platforms, leading to incomplete cross-protection and the risk of antibody-dependent enhancement. Long-term durability is exemplified by YF-17D, which induces protective antibodies that have been detectable for decades, whereas the JE SA14-14-2 vaccine has achieved program-level reductions in disease in endemic regions. In contrast, CYD-TDV shows serostatus-dependent outcomes, and the investigational TAK-003 vaccine has demonstrated antibody persistence for at least four years. Recent studies have clarified how preserving quaternary envelope epitopes, minimizing prM-associated non-neutralizing specificity, and sustaining germinal center activity determine antibody affinity, breadth, and persistence. Advances in adjuvant formulations and delivery platforms have shown that engaging defined innate pathways and prolonging antigen availability enhance affinity maturation and long-lived plasma cell formation. Booster scheduling and baseline serostatus further shape the antibody quality, highlighting the importance of immune imprinting and cross-reactivity in vaccine design. Together, these findings outline the design principles for next-generation flavivirus vaccines, including stabilization of neutralization-sensitive epitopes, use of adjuvants that sustain germinal center responses, optimization of antigen persistence, and tailoring of dosing strategies to immune history to elicit durable and broadly protective humoral immunity.<\/jats:p>","DOI":"10.3390\/vaccines13121182","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:17:23Z","timestamp":1763734643000},"page":"1182","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing Humoral Immunity for Durable and Broad Protection in Flavivirus Vaccines"],"prefix":"10.3390","volume":"13","author":[{"given":"Jae-Yeon","family":"Park","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6382-3434","authenticated-orcid":false,"given":"Hye-Mi","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0140-6736(08)60238-X","article-title":"Pathogenic flaviviruses","volume":"371","author":"Gould","year":"2008","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41564-020-0714-0","article-title":"The continued threat of emerging flaviviruses","volume":"5","author":"Pierson","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Park, J.Y., and Lee, H.M. (2025). Managing Japanese Encephalitis Virus as a Veterinary Infectious Disease Through Animal Surveillance and One Health Control Strategies. Life, 15.","DOI":"10.3390\/life15081260"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0065-3527(03)59002-9","article-title":"Molecular biology of flaviviruses","volume":"59","author":"Lindenbach","year":"2003","journal-title":"Adv. Virus Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Park, J.Y., Lee, H.M., Jun, S.H., Kamitani, W., Kim, O., and Shin, H.J. (2024). Insights into the Pathogenesis and Development of Recombinant Japanese Encephalitis Virus Genotype 3 as a Vaccine. Vaccines, 12.","DOI":"10.3390\/vaccines12060597"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e70608","DOI":"10.1002\/jmv.70608","article-title":"Japanese Encephalitis Virus Genotype 5 Infectious Clone and Reporter System for Antiviral Evaluation","volume":"97","author":"Park","year":"2025","journal-title":"J. Med. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13975","DOI":"10.1128\/JVI.78.24.13975-13986.2004","article-title":"Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes","volume":"78","author":"Crill","year":"2004","journal-title":"J. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","article-title":"The current and future global distribution and population at risk of dengue","volume":"4","author":"Messina","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J. Clin. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3201\/eid0601.000103","article-title":"Japanese encephalitis immunization in South Korea: Past, present, and future","volume":"6","author":"Sohn","year":"2000","journal-title":"Emerg. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: A systematic review","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull. World Health Organ."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1080\/21645515.2017.1285472","article-title":"Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease","volume":"13","author":"Hegde","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri3916","article-title":"New insights into the immunopathology and control of dengue virus infection","volume":"15","author":"Screaton","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1128\/JVI.00252-16","article-title":"Zika Virus: New Clinical Syndromes and Its Emergence in the Western Hemisphere","volume":"90","author":"Lazear","year":"2016","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41586-018-0446-y","article-title":"The emergence of Zika virus and its new clinical syndromes","volume":"560","author":"Pierson","year":"2018","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.virol.2010.12.020","article-title":"Antibody-mediated neutralization of flaviviruses: A reductionist view","volume":"411","author":"Dowd","year":"2011","journal-title":"Virology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1073\/pnas.1522136113","article-title":"Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort","volume":"113","author":"Katzelnick","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nri3802","article-title":"Memory B cells","volume":"15","author":"Kurosaki","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.15252\/embr.201745302","article-title":"The bright and the dark side of human antibody responses to flaviviruses: Lessons for vaccine design","volume":"19","author":"Rey","year":"2018","journal-title":"EMBO Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.cell.2020.09.063","article-title":"Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates","volume":"183","author":"Viant","year":"2020","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev-immunol-020711-075032","article-title":"Germinal centers","volume":"30","author":"Victora","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/S1473-3099(16)30473-X","article-title":"Dengue: Knowledge gaps, unmet needs, and research priorities","volume":"17","author":"Katzelnick","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1073\/pnas.1607931113","article-title":"Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus","volume":"113","author":"Priyamvada","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ni.3058","article-title":"A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus","volume":"16","author":"Dejnirattisai","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature14130","article-title":"Recognition determinants of broadly neutralizing human antibodies against dengue viruses","volume":"520","author":"Rouvinski","year":"2015","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coi.2017.06.008","article-title":"Germinal center enhancement by extended antigen availability","volume":"47","author":"Cirelli","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T Follicular Helper Cell Biology: A Decade of Discovery and Diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-065X.2012.01124.x","article-title":"Germinal center selection and the development of memory B and plasma cells","volume":"247","author":"Shlomchik","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","article-title":"The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response","volume":"183","author":"Akondy","year":"2009","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.4049\/jimmunol.1700083","article-title":"A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine","volume":"199","author":"Hou","year":"2017","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ghosh, D., and Basu, A. (2009). Japanese encephalitis-a pathological and clinical perspective. PLoS Negl. Trop. Dis., 3.","DOI":"10.1371\/journal.pntd.0000437"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.ai.2016.11.002","article-title":"Molecular Mechanisms of Somatic Hypermutation and Class Switch Recombination","volume":"133","author":"Methot","year":"2017","journal-title":"Adv. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1126\/science.aad3439","article-title":"Visualizing antibody affinity maturation in germinal centers","volume":"351","author":"Tas","year":"2016","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1073\/pnas.1200566109","article-title":"Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions","volume":"109","author":"Smith","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lightman, S.M., Utley, A., and Lee, K.P. (2019). Survival of Long-Lived Plasma Cells (LLPC): Piecing Together the Puzzle. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00965"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Slamanig, S.A., and Nolte, M.A. (2021). The Bone Marrow as Sanctuary for Plasma Cells and Memory T-Cells: Implications for Adaptive Immunity and Vaccinology. Cells, 10.","DOI":"10.3390\/cells10061508"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wieten, R.W., Jonker, E.F., van Leeuwen, E.M., Remmerswaal, E.B., Ten Berge, I.J., de Visser, A.W., van Genderen, P.J., Goorhuis, A., Visser, L.G., and Grobusch, M.P. (2016). A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses After Vaccination. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149871"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6802a1","article-title":"Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Hills","year":"2019","journal-title":"MMWR Recomm. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1017\/S1462399408000665","article-title":"Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection","volume":"10","author":"Pierson","year":"2008","journal-title":"Expert. Rev. Mol. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrmicro1067","article-title":"A structural perspective of the flavivirus life cycle","volume":"3","author":"Mukhopadhyay","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11567","DOI":"10.1128\/JVI.05859-11","article-title":"Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms","volume":"85","author":"Vogt","year":"2011","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1126\/science.aai8128","article-title":"IgG antibodies to dengue enhanced for FcgammaRIIIA binding determine disease severity","volume":"355","author":"Wang","year":"2017","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0065-3527(03)60011-4","article-title":"Neutralization and antibody-dependent enhancement of dengue viruses","volume":"60","author":"Halstead","year":"2003","journal-title":"Adv. Virus Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrmicro.2015.2","article-title":"Dengue vaccine: Hypotheses to understand CYD-TDV-induced protection","volume":"14","author":"Guy","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2017.03.016","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"169","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: Mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"eadi8039","DOI":"10.1126\/sciimmunol.adi8039","article-title":"AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans","volume":"9","author":"Grigoryan","year":"2024","journal-title":"Sci. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Reinke, S., Thakur, A., Gartlan, C., Bezbradica, J.S., and Milicic, A. (2020). Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants. Vaccines, 8.","DOI":"10.3390\/vaccines8030554"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Chiu, N.C., Lin, C.Y., Chen, C., Cheng, H.Y., Hsieh, E.F., Liu, L.T., Chiu, C.H., and Huang, L.M. (2024). Long-Term Immunogenicity Study of an Aluminum Phosphate-Adjuvanted Inactivated Enterovirus A71 Vaccine in Children: An Extension to a Phase 2 Study. Vaccines, 12.","DOI":"10.2139\/ssrn.4898445"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1080\/21645515.2021.1969852","article-title":"Safety of Japanese encephalitis vaccines","volume":"17","author":"Hu","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.vaccine.2013.05.007","article-title":"The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect","volume":"31","author":"Calabro","year":"2013","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.1402604","article-title":"Oil-in-Water Emulsion MF59 Increases Germinal Center B Cell Differentiation and Persistence in Response to Vaccination","volume":"195","author":"Lofano","year":"2015","journal-title":"J. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41541-021-00418-0","article-title":"\u201cWorld in motion\u201d\u2014Emulsion adjuvants rising to meet the pandemic challenges","volume":"6","author":"Lodaya","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and efficacy of MF59-adjuvanted vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2567.2001.01158.x","article-title":"Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens","volume":"102","author":"Kovarik","year":"2001","journal-title":"Immunology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1016\/j.vaccine.2014.06.065","article-title":"Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer","volume":"32","author":"Scheiermann","year":"2014","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1586\/erv.11.18","article-title":"Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer","volume":"10","author":"Ragupathi","year":"2011","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Chen, K., Wang, N., Zhang, X., Wang, M., Liu, Y., and Shi, Y. (2023). Potentials of saponins-based adjuvants for nasal vaccines. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1153042"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Yoon, M., Choi, Y., Wi, T., Choi, Y.S., and Choi, J. (2024). The role of cGAMP via the STING pathway in modulating germinal center responses and CD4 T cell differentiation. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1340001"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","article-title":"A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses Against SARS-CoV-2 in Mice","volume":"53","author":"Laczko","year":"2020","journal-title":"Immunity"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcdb.2020.12.008","article-title":"Aluminium adjuvants in vaccines\u2014A way to modulate the immune response","volume":"115","author":"Danielsson","year":"2021","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e2250133","DOI":"10.1002\/eji.202250133","article-title":"YF17D-based vaccines\u2014Standing on the shoulders of a giant","volume":"54","author":"Alpizar","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wang, P. (2021). Natural and Synthetic Saponins as Vaccine Adjuvants. Vaccines, 9.","DOI":"10.3390\/vaccines9030222"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.chom.2018.05.021","article-title":"Zika Virus Vaccine: Progress and Challenges","volume":"24","author":"Shan","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1099\/jmm.0.038943-0","article-title":"Alum adjuvant: Some of the tricks of the oldest adjuvant","volume":"61","author":"Kool","year":"2012","journal-title":"J. Med. Microbiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4049\/jimmunol.181.1.17","article-title":"Cutting edge: Inflammasome activation by alum and alum\u2019s adjuvant effect are mediated by NLRP3","volume":"181","author":"Li","year":"2008","journal-title":"J. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/eji.200838549","article-title":"The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity","volume":"38","author":"Franchi","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/imj.12189","article-title":"Tick-borne encephalitis vaccines","volume":"43","author":"Unger","year":"2013","journal-title":"Intern. Med. J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4161\/21645515.2014.983412","article-title":"Product review on the JE vaccine IXIARO","volume":"11","author":"Firbas","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/1521-4141(2001010)31:10<2910::AID-IMMU2910>3.0.CO;2-3","article-title":"Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis","volume":"31","author":"Dupuis","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-021-00289-5","article-title":"Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults","volume":"6","author":"Li","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4269\/ajtmh.19-0738","article-title":"Safety and Immunogenicity of an AS03(B)-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1\/2 Randomized Study","volume":"103","author":"Lin","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4269\/ajtmh.19-0461","article-title":"Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study","volume":"102","author":"Diaz","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune adjuvants","volume":"29","author":"Steinhagen","year":"2011","journal-title":"Vaccine"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/eji.200636800","article-title":"Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion","volume":"37","author":"Katsenelson","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.4049\/jimmunol.1000768","article-title":"TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis","volume":"185","author":"Demento","year":"2010","journal-title":"J. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Goetz, M., Thotathil, N., Zhao, Z., and Mitragotri, S. (2024). Vaccine adjuvants for infectious disease in the clinic. Bioeng. Transl. Med., 9.","DOI":"10.1002\/btm2.10663"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/vaccines2020323","article-title":"Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands","volume":"2","author":"Toussi","year":"2014","journal-title":"Vaccines"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.vaccine.2005.03.042","article-title":"An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model","volume":"23","author":"Coller","year":"2005","journal-title":"Vaccine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1479-5876-10-4","article-title":"Effects of adjuvants on IgG subclasses elicited by virus-like particles","volume":"10","author":"Visciano","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2337985","DOI":"10.1080\/21645515.2024.2337985","article-title":"A systematic review on malaria and dengue vaccines for the effective management of these mosquito borne diseases: Improving public health","volume":"20","author":"Kanan","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1172\/JCI79915","article-title":"Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants","volume":"125","author":"Hanson","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4049\/jimmunol.1801323","article-title":"Cyclic Dinucleotide-Adjuvanted Dengue Virus Nonstructural Protein 1 Induces Protective Antibody and T Cell Responses","volume":"202","author":"Espinosa","year":"2019","journal-title":"J. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Shen, Y., Huang, W., Nie, J., and Zhang, L. (2025). Progress Update on STING Agonists as Vaccine Adjuvants. Vaccines, 13.","DOI":"10.3390\/vaccines13040371"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Wollner, C.J., and Richner, J.M. (2021). mRNA Vaccines against Flaviviruses. Vaccines, 9.","DOI":"10.3390\/vaccines9020148"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40506-020-00242-5","article-title":"Japanese Encephalitis Vaccines","volume":"12","author":"Satchidanandam","year":"2020","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"eabg4084","DOI":"10.1126\/sciadv.abg4084","article-title":"Designed, highly expressing, thermostable dengue virus 2 envelope protein dimers elicit quaternary epitope antibodies","volume":"7","author":"Kudlacek","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1016\/j.cell.2021.11.010","article-title":"The epitope arrangement on flavivirus particles contributes to Mab C10\u2019s extraordinary neutralization breadth across Zika and dengue viruses","volume":"184","author":"Sharma","year":"2021","journal-title":"Cell"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Gallichotte, E.N., Widman, D.G., Yount, B.L., Wahala, W.M., Durbin, A., Whitehead, S., Sariol, C.A., Crowe, J.E., de Silva, A.M., and Baric, R.S. (2015). A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. mBio, 6.","DOI":"10.1128\/mBio.01461-15"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Phan, T.T.N., Hvasta, M.G., Kudlacek, S.T., Thiono, D.J., Tripathy, A., Nicely, N.I., de Silva, A.M., and Kuhlman, B. (2022). A conserved set of mutations for stabilizing soluble envelope protein dimers from dengue and Zika viruses to advance the development of subunit vaccines. J. Biol. Chem., 298.","DOI":"10.1016\/j.jbc.2022.102079"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.1128\/JVI.00170-10","article-title":"In vitro reconstitution reveals key intermediate states of trimer formation by the dengue virus membrane fusion protein","volume":"84","author":"Liao","year":"2010","journal-title":"J. Virol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e38970","DOI":"10.7554\/eLife.38970","article-title":"Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody","volume":"7","author":"Shen","year":"2018","journal-title":"eLife"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Metz, S.W., Gallichotte, E.N., Brackbill, A., Premkumar, L., Miley, M.J., Baric, R., and de Silva, A.M. (2017). In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-04767-6"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Whitehead, S.S., Durbin, A.P., Pierce, K.K., Elwood, D., McElvany, B.D., Fraser, E.A., Carmolli, M.P., Tibery, C.M., Hynes, N.A., and Jo, M. (2017). In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005584"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"100155","DOI":"10.1016\/j.xcrm.2020.100155","article-title":"Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003","volume":"1","author":"Tu","year":"2020","journal-title":"Cell Rep. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1097\/INF.0000000000002124","article-title":"Antibody Persistence up to 3 Years After Primary Immunization with Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose","volume":"37","author":"Kadlecek","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1016\/j.vaccine.2015.05.037","article-title":"Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis","volume":"33","author":"Kollaritsch","year":"2015","journal-title":"Vaccine"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Tripathi, N.K., and Shrivastava, A. (2018). Recent Developments in Recombinant Protein-Based Dengue Vaccines. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01919"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.chembiol.2022.02.004","article-title":"Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses in vivo","volume":"29","author":"Georgiev","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-018-0077-1","article-title":"A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen","volume":"3","author":"Wiley","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice","volume":"18","author":"Zhang","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41541-021-00307-6","article-title":"Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates","volume":"6","author":"Saunders","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.1128\/JVI.02724-07","article-title":"A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus","volume":"82","author":"Raviprakash","year":"2008","journal-title":"J. Virol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Bullard, B.L., Corder, B.N., Gordon, D.N., Pierson, T.C., and Weaver, E.A. (2020). Characterization of a Species E Adenovirus Vector as a Zika virus vaccine. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-60238-5"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"001588","DOI":"10.1099\/jgv.0.001588","article-title":"Induction of protective immune responses against a lethal Zika virus challenge post-vaccination with a dual serotype of recombinant vesicular stomatitis virus carrying the genetically modified Zika virus E protein gene","volume":"102","author":"Choi","year":"2021","journal-title":"J. Gen. Virol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Taslem Mourosi, J., Awe, A., Jain, S., and Batra, H. (2022). Nucleic Acid Vaccine Platform for DENGUE and ZIKA Flaviviruses. Vaccines, 10.","DOI":"10.3390\/vaccines10060834"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.tibtech.2023.05.007","article-title":"Rise of the RNA machines\u2014Self-amplification in mRNA vaccine design","volume":"41","author":"Comes","year":"2023","journal-title":"Trends Biotechnol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.ymthe.2025.03.060","article-title":"The advent of clinical self-amplifying RNA vaccines","volume":"33","author":"Casmil","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Metz, S.W., Thomas, A., Brackbill, A., Xianwen, Y., Stone, M., Horvath, K., Miley, M.J., Luft, C., DeSimone, J.M., and Tian, S. (2018). Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006793"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Silva, E.F., Orsi, M., Andrade, A.L., Domingues, R.Z., Silva, B.M., de Araujo, H.R., Pimenta, P.F., Diamond, M.S., Rocha, E.S., and Kroon, E.G. (2012). A tetravalent dengue nanoparticle stimulates antibody production in mice. J. Nanobiotechnol., 10.","DOI":"10.1186\/1477-3155-10-13"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.coviro.2020.07.006","article-title":"Mapping the diverse structural landscape of the flavivirus antibody repertoire","volume":"45","author":"Sevvana","year":"2020","journal-title":"Curr. Opin. Virol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Gunawardana, S.A., and Shaw, R.H. (2018). Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora\u2019s box?. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3572-0"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Rodenhuis-Zybert, I.A., van der Schaar, H.M., da Silva Voorham, J.M., van der Ende-Metselaar, H., Lei, H.Y., Wilschut, J., and Smit, J.M. (2010). Immature dengue virus: A veiled pathogen?. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000718"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.str.2018.10.009","article-title":"Mechanism of Enhanced Immature Dengue Virus Attachment to Endosomal Membrane Induced by prM Antibody","volume":"27","author":"Wirawan","year":"2019","journal-title":"Structure"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Zhao, R., Wang, M., Cao, J., Shen, J., Zhou, X., Wang, D., and Cao, J. (2021). Flavivirus: From Structure to Therapeutics Development. Life, 11.","DOI":"10.3390\/life11070615"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Dutta, S.K., and Langenburg, T. (2023). A Perspective on Current Flavivirus Vaccine Development: A Brief Review. Viruses, 15.","DOI":"10.3390\/v15040860"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1128\/JVI.03144-12","article-title":"JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody","volume":"87","author":"Larena","year":"2013","journal-title":"J. Virol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Araujo, S.C., Pereira, L.R., Alves, R.P.S., Andreata-Santos, R., Kanno, A.I., Ferreira, L.C.S., and Goncalves, V.M. (2020). Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced in Escherichia coli. Vaccines, 8.","DOI":"10.3390\/vaccines8030492"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4149\/av_2016_01_3","article-title":"Dengue vaccine: An update on recombinant subunit strategies","volume":"60","author":"Martin","year":"2016","journal-title":"Acta Virol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1007\/s00253-018-8822-y","article-title":"Dengue viruses and promising envelope protein domain III-based vaccines","volume":"102","author":"Fahimi","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Wong, S.H., Jassey, A., Wang, J.Y., Wang, W.C., Liu, C.H., and Lin, L.T. (2019). Virus-Like Particle Systems for Vaccine Development against Viruses in the Flaviviridae Family. Vaccines, 7.","DOI":"10.3390\/vaccines7040123"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Unali, G., and Douam, F. (2025). Orthoflavivirus Vaccine Platforms: Current Strategies and Challenges. Vaccines, 13.","DOI":"10.3390\/vaccines13101015"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Ebel, H., Benecke, T., and Vollmer, B. (2022). Stabilisation of Viral Membrane Fusion Proteins in Pre-fusion Conformation by Structure-Based Design for Structure Determination and Vaccine Development. Viruses, 14.","DOI":"10.3390\/v14081816"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12985-018-1092-6","article-title":"Crystal structure of Usutu virus envelope protein in the pre-fusion state","volume":"15","author":"Chen","year":"2018","journal-title":"Virol. J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e04389","DOI":"10.7554\/eLife.04389","article-title":"Sequential conformational rearrangements in flavivirus membrane fusion","volume":"3","author":"Chao","year":"2014","journal-title":"eLife"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"He, J., Ding, X., Zhao, J., Zeng, J., Zhou, Y., Xiao, W., Hua, D., Liu, M., Guo, H., and Zhang, Y. (2024). A novel pan-epitope based nanovaccine self-assembled with CpG enhances immune responses against flavivirus. J. Nanobiotechnol., 22.","DOI":"10.1186\/s12951-024-03031-0"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.bpj.2016.09.003","article-title":"Modeling the Role of Epitope Arrangement on Antibody Binding Stoichiometry in Flaviviruses","volume":"111","author":"Ripoll","year":"2016","journal-title":"Biophys. J."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Blakney, A.K., Ip, S., and Geall, A.J. (2021). An Update on Self-Amplifying mRNA Vaccine Development. Vaccines, 9.","DOI":"10.3390\/vaccines9020097"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Silva-Pilipich, N., Beloki, U., Salaberry, L., and Smerdou, C. (2024). Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19. Vaccines, 12.","DOI":"10.3390\/vaccines12030318"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Battisti, P., Ykema, M.R., Kasal, D.N., Jennewein, M.F., Beaver, S., Weight, A.E., Hanson, D., Singh, J., Bakken, J., and Cross, N. (2025). A bivalent self-amplifying RNA vaccine against yellow fever and Zika viruses. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1569454"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Rathore, A.P.S., and St John, A.L. (2020). Cross-Reactive Immunity Among Flaviviruses. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00334"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.chom.2018.10.016","article-title":"Cross-Reactive Flavivirus Antibody: Friend and Foe?","volume":"24","author":"Maciejewski","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Swanstrom, J.A., Plante, J.A., Plante, K.S., Young, E.F., McGowan, E., Gallichotte, E.N., Widman, D.G., Heise, M.T., de Silva, A.M., and Baric, R.S. (2016). Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus. mBio, 7.","DOI":"10.1128\/mBio.01123-16"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e03048-23","DOI":"10.1128\/mbio.03048-23","article-title":"Defining the impact of flavivirus envelope protein glycosylation site mutations on sensitivity to broadly neutralizing antibodies","volume":"15","author":"Contreras","year":"2024","journal-title":"mBio"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.aaa8651","article-title":"DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers","volume":"349","author":"Fibriansah","year":"2015","journal-title":"Science"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/ni.3849","article-title":"Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection","volume":"18","author":"Fernandez","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni.3515","article-title":"Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus","volume":"17","author":"Dejnirattisai","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Sun, J., Du, S., Zheng, Z., Cheng, G., and Jin, X. (2020). Defeat Dengue and Zika Viruses with a One-Two Punch of Vaccine and Vector Blockade. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.00362"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.7150\/thno.35919","article-title":"Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization","volume":"9","author":"Lin","year":"2019","journal-title":"Theranostics"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1128\/JVI.01826-10","article-title":"An in-depth analysis of original antigenic sin in dengue virus infection","volume":"85","author":"Midgley","year":"2011","journal-title":"J. Virol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1126\/science.abb6143","article-title":"Zika virus infection enhances future risk of severe dengue disease","volume":"369","author":"Katzelnick","year":"2020","journal-title":"Science"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"eadh3067","DOI":"10.1126\/scitranslmed.adh3067","article-title":"Insights into dengue immunity from vaccine trials","volume":"15","author":"Ooi","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Dussupt, V., Modjarrad, K., and Krebs, S.J. (2020). Landscape of Monoclonal Antibodies Targeting Zika and Dengue: Therapeutic Solutions and Critical Insights for Vaccine Development. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.621043"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41577-019-0123-x","article-title":"Adaptive immune responses to primary and secondary dengue virus infections","volume":"19","author":"Rathore","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"World Health Organization (2019). Dengue vaccine: WHO position paper, September 2018\u2014Recommendations. Vaccine, 37, 4848\u20134849.","DOI":"10.1016\/j.vaccine.2018.09.063"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nature18938","article-title":"Structural basis of potent Zika-dengue virus antibody cross-neutralization","volume":"536","author":"Dejnirattisai","year":"2016","journal-title":"Nature"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/infdis\/jiz618","article-title":"Antibody-Dependent Enhancement of Severe Disease Is Mediated by Serum Viral Load in Pediatric Dengue Virus Infections","volume":"221","author":"Waggoner","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e65131","DOI":"10.7554\/eLife.65131","article-title":"Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data","volume":"10","author":"Laydon","year":"2021","journal-title":"eLife"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"eabg9478","DOI":"10.1126\/scitranslmed.abg9478","article-title":"Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term","volume":"13","author":"Katzelnick","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s41590-019-0477-z","article-title":"A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection","volume":"20","author":"Dejnirattisai","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"eabf1152","DOI":"10.1126\/sciimmunol.abf1152","article-title":"A particulate saponin\/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity","volume":"6","author":"Silva","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"100143","DOI":"10.1016\/j.jvacx.2022.100143","article-title":"Antibody persistence and immune memory response following primary vaccination and boosting with live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) in Bangladesh: A phase 4 open-label clinical trial","volume":"10","author":"Zaman","year":"2022","journal-title":"Vaccine X"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1073\/pnas.1921388117","article-title":"Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine","volume":"117","author":"Wec","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/21645515.2018.1515455","article-title":"Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine","volume":"15","author":"Bouckenooghe","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1093\/cid\/ciac580","article-title":"Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis","volume":"75","author":"Kling","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e0096323","DOI":"10.1128\/jvi.00963-23","article-title":"Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques","volume":"97","author":"Keelapang","year":"2023","journal-title":"J. Virol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4110\/in.2011.11.5.268","article-title":"Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2","volume":"11","author":"George","year":"2011","journal-title":"Immune Netw."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Salem, G.M., Galula, J.U., Wu, S.R., Liu, J.H., Chen, Y.H., Wang, W.H., Wang, S.F., Song, C.S., Chen, F.C., and Abarientos, A.B. (2024). Antibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus. Commun. Biol., 7.","DOI":"10.1038\/s42003-024-05963-7"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/jimmun\/vkae039","article-title":"The cellular factors that impair the germinal center in advanced age","volume":"214","author":"Foster","year":"2025","journal-title":"J. Immunol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2021.11.001","article-title":"Mechanisms underpinning poor antibody responses to vaccines in ageing","volume":"241","author":"Lee","year":"2022","journal-title":"Immunol. Lett."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri2508","article-title":"B-cell responses to vaccination at the extremes of age","volume":"9","author":"Siegrist","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1126\/science.aav6618","article-title":"Impact of pre-existing dengue immunity on Zika virus emergence in a dengue endemic region","volume":"363","author":"Costa","year":"2019","journal-title":"Science"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Palacios-Pedrero, M.A., Osterhaus, A., Becker, T., Elbahesh, H., Rimmelzwaan, G.F., and Saletti, G. (2021). Aging and Options to Halt Declining Immunity to Virus Infections. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.681449"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/14760584.2019.1604231","article-title":"Selection of adjuvants for vaccines targeting specific pathogens","volume":"18","author":"Sarkar","year":"2019","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41541-024-00874-4","article-title":"Insights into vaccines for elderly individuals: From the impacts of immunosenescence to delivery strategies","volume":"9","author":"Hou","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41541-024-00875-3","article-title":"Sustained antigen delivery improves germinal center reaction and increases antibody responses in neonatal mice","volume":"9","author":"Parvathaneni","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e183400","DOI":"10.1172\/jci.insight.183400","article-title":"BAFF promotes follicular helper T cell development and germinal center formation through BR3 signal","volume":"9","author":"Chen","year":"2024","journal-title":"JCI Insight"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1084\/jem.20160832","article-title":"Plasma cell output from germinal centers is regulated by signals from Tfh and stromal cells","volume":"215","author":"Zhang","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Vassilieva, E.V., Taylor, D.W., and Compans, R.W. (2019). Combination of STING Pathway Agonist with Saponin Is an Effective Adjuvant in Immunosenescent Mice. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.03006"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Anasir, M.I., and Poh, C.L. (2019). Structural Vaccinology for Viral Vaccine Design. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.00738"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12985-025-02645-6","article-title":"Revolutionizing immunization: A comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol. J."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Flores, H.E., Pinzon Burgos, E.F., Camacho Ortega, S., Heredia, A., and Chua, J.V. (2025). From Antibodies to Immunity: Assessing Correlates of Flavivirus Protection and Cross-Reactivity. Vaccines, 13.","DOI":"10.3390\/vaccines13050449"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.immuni.2024.03.015","article-title":"Vaccine adjuvants: Tailoring innate recognition to send the right message","volume":"57","author":"Lavelle","year":"2024","journal-title":"Immunity"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s12250-019-00093-5","article-title":"Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure","volume":"34","author":"Yang","year":"2019","journal-title":"Virol. Sin."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"eadn7187","DOI":"10.1126\/sciadv.adn7187","article-title":"Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses","volume":"10","author":"Ou","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Deng, S.Q., Yang, X., Wei, Y., Chen, J.T., Wang, X.J., and Peng, H.J. (2020). A Review on Dengue Vaccine Development. Vaccines, 8.","DOI":"10.3390\/vaccines8010063"},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Cui, J.Z., Xiong, X.H., Wang, Q.Y., Dong, H.L., Liu, G., and Chen, H.P. (2025). Insect-Specific Flaviviruses Have Potential Applications as a Scaffold for Pathogenic Flavivirus Vaccines. Vaccines, 13.","DOI":"10.3390\/vaccines13070769"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"105318","DOI":"10.1016\/j.micinf.2024.105318","article-title":"Systems vaccinology studies\u2014Achievements and future potential","volume":"26","author":"Sugrue","year":"2024","journal-title":"Microbes Infect."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Plotkin, S.A. (2022). Recent updates on correlates of vaccine-induced protection. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1081107"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"127219","DOI":"10.1016\/j.vaccine.2025.127219","article-title":"A novel immunogen comprising a bc loop and mutant fusion loop epitopes generates potent neutralization and protective abilities against flaviviruses without risk of disease enhancement","volume":"57","author":"Lien","year":"2025","journal-title":"Vaccine"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Thomas, A., Thiono, D.J., Kudlacek, S.T., Forsberg, J., Premkumar, L., Tian, S., Kuhlman, B., de Silva, A.M., and Metz, S.W. (2020). Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus. J. Virol., 94.","DOI":"10.1128\/JVI.00745-20"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"eabb1025","DOI":"10.1126\/sciimmunol.abb1025","article-title":"3M-052, a synthetic TLR-7\/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates","volume":"5","author":"Kasturi","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"eaba5068","DOI":"10.1126\/sciadv.aba5068","article-title":"Development of a potent Zika virus vaccine using self-amplifying messenger RNA","volume":"6","author":"Luisi","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: The results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41590-022-01328-6","article-title":"Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses","volume":"23","author":"Hagan","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/21645515.2019.1697110","article-title":"Methods for predicting vaccine immunogenicity and reactogenicity","volume":"16","author":"Lee","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1099\/jgv.0.001271","article-title":"A heterologous prime-boost strategy for immunization against Dengue virus combining the Tetra DIIIC subunit vaccine candidate with the TV005 live-attenuated tetravalent vaccine","volume":"100","author":"Valdes","year":"2019","journal-title":"J. Gen. Virol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1016\/j.vaccine.2021.10.017","article-title":"T cell and memory B cell responses in tetravalent DNA, tetravalent inactivated and tetravalent live-attenuated prime-boost dengue vaccines in rhesus macaques","volume":"39","author":"Sun","year":"2021","journal-title":"Vaccine"},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"De Lorenzo, G., Tandavanitj, R., Preciado-Llanes, L., Sanchez-Velazquez, R., Prado Rocha, R., Kim, Y.C., Reyes-Sandoval, A., and Patel, A.H. (2025). Heterologous prime-boost Zika virus vaccination induces comprehensive humoral and cellular immunity in mouse models. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1578427"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Natsrita, P., Charoenkwan, P., Shoombuatong, W., Mahalapbutr, P., Faksri, K., Chareonsudjai, S., Rungrotmongkol, T., and Pipattanaboon, C. (2024). Machine-learning-assisted high-throughput identification of potent and stable neutralizing antibodies against all four dengue virus serotypes. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-67487-8"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Bergamaschi, G., Fassi, E.M.A., Romanato, A., D\u2019Annessa, I., Odinolfi, M.T., Brambilla, D., Damin, F., Chiari, M., Gori, A., and Colombo, G. (2019). Computational Analysis of Dengue Virus Envelope Protein (E) Reveals an Epitope with Flavivirus Immunodiagnostic Potential in Peptide Microarrays. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20081921"},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Deepthi, V., Sasikumar, A., Mohanakumar, K.P., and Rajamma, U. (2025). Computationally designed multi-epitope vaccine construct targeting the SARS-CoV-2 spike protein elicits robust immune responses in silico. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-92956-z"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2214-109X(23)00556-9","article-title":"Long-term immunity following yellow fever vaccination: A systematic review and meta-analysis","volume":"12","author":"Schnyder","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Sarker, A., Dhama, N., and Gupta, R.D. (2023). Dengue virus neutralizing antibody: A review of targets, cross-reactivity, and antibody-dependent enhancement. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1200195"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Shukla, R., Ramasamy, V., Shanmugam, R.K., Ahuja, R., and Khanna, N. (2020). Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine. Front. Cell Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.572681"},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Chan, K.R., Ismail, A.A., Thergarajan, G., Raju, C.S., Yam, H.C., Rishya, M., and Sekaran, S.D. (2022). Serological cross-reactivity among common flaviviruses. Front. Cell Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.975398"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Parra-Gonzalez, M., Najera-Maldonado, L., Peralta-Cuevas, E., Gutierrez-Onofre, A.J., Garcia-Atutxa, I., and Villanueva-Flores, F. (2025). Overcoming dengue vaccine challenges through next-generation virus-like particle immunization strategies. Front. Cell Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1614805"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"101946","DOI":"10.1016\/j.xcrm.2025.101946","article-title":"Basal T cell activation predicts yellow fever vaccine response independently of cytomegalovirus infection and sex-related immune variations","volume":"6","author":"Zaucha","year":"2025","journal-title":"Cell Rep. Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/12\/1182\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:24:05Z","timestamp":1763735045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/12\/1182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":216,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["vaccines13121182"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13121182","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}